Cocrystal Pharma, Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| COCRYSTAL PHARMA, INC. | ||
| March 31, 2026 | By: | /s/ James Martin |
|---|---|---|
| James Martin | ||
| Co-Chief Executive Officer | ||
| (Principal Executive Officer) | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| SIGNATURE | TITLE | DATE |
|---|---|---|
| /s/ Roger Kornberg | Chairman | March 31, 2026 |
| Roger Kornberg | ||
| /s/ Phillip Frost | Director | March 31, 2026 |
| Phillip Frost | ||
| /s/ Fred Hassan | Director | March 31, 2026 |
| Fred Hassan | ||
| /s/ Richard Pfenniger | Director | March 31, 2026 |
| Richard Pfenniger | ||
| /s/ Steven Rubin | Director | March 31, 2026 |
| Steven Rubin | ||
| /s/ James Martin | Chief Financial Officer and Co-Chief Executive Officer | March 31, 2026 |
| James Martin | (Principal Financial, Accounting and Executive Officer) | |
| /s/ Sam Lee | President and Co-Chief Executive Officer | March 31, 2026 |
| Sam Lee | (Principal Executive Officer) | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.